Chief Executive Officer — Care-Delivery Network

The mandate

A care-delivery network serving metropolitan and regional communities requires stronger integration of clinical assurance, operating authority and capital decisions. The board has created an urgent Chief Executive Officer appointment because the present structure separates these functions too widely, and local accountability needs to be rebuilt across several sites.

The enterprise brings together ambulatory, day-procedure, post-acute and home-linked services. Approximately 700 employees and material partners work across care delivery, nursing, medical leadership, access, revenue cycle, quality, technology and local operations. The new CEO will control the operating plan, leadership appointments, capital priorities and network standards, reporting to the Group board and Group Chief Executive. Licensed clinicians retain their professional duties; the CEO must build conditions in which those duties can be discharged consistently.

The first obligation is to establish an honest clinical baseline. Harm reviews, near misses, complaints, unplanned transfers, readmissions and overdue follow-up currently sit in different systems and use different thresholds. The CEO will commission one case-based review method, protect speaking up and insist that closure means evidence of changed practice rather than an action entered in a tracker. Findings must reach the board without local dilution or defensive aggregation.

Recovery cannot become a quality-office project. Site executives, medical leaders and nursing leaders will receive explicit joint accountability for staffing, patient flow, escalation and controlled discharge. The CEO will clarify which decisions belong at the bedside, which sit with a site and which require network intervention. Repeated exceptions will trigger resource or leadership action, not another reminder to follow policy.

Patient journeys cross organisational boundaries. A referral may start with a community practitioner, pass through diagnostics and procedure, then depend on pharmacy, rehabilitation or home support. The CEO must reduce lost hand-offs by introducing named ownership at high-risk transitions, reliable receipt confirmation and rapid escalation when capacity prevents the intended pathway. Patients and carers need understandable instructions and a route back into the network when symptoms change.

Workforce recovery will be treated as clinical infrastructure. Agency dependence, fatigue, supervision gaps and uneven skill mix have produced fragile rosters even where nominal headcount appears adequate. The CEO will align establishment with acuity and operating hours, rebuild preceptor capacity and make unsafe coverage visible before a shift begins. Retention work must distinguish chronic management behaviour from market scarcity and respond accordingly.

The capital portfolio includes ageing clinical equipment, digital workflow requests and facility upgrades. Investments will be ranked by safety exposure, service continuity and pathway benefit, with benefits owners named before approval. A visually attractive expansion will not outrank replacement of a failure-prone asset merely because the latter is less commercially exciting. Deferred maintenance and temporary workarounds must appear in the same decision record.

Financial recovery matters because unreliable margins constrain safe staffing and renewal. The CEO will work with finance on service-line economics that include cancellations, rework, premium labour, denied claims and downstream burden. Closing a low-volume service may solve an accounting problem while worsening access or transfers elsewhere; such choices require total-pathway evidence and consultation with affected clinical leaders.

Relationships with medical practitioners demand particular judgement. The network relies on employed, affiliated and visiting clinicians whose incentives and influence differ. Credentialling, scope, peer review and performance concerns must be governed consistently without confusing commercial contribution with clinical standing. The CEO must be comfortable having a direct, fair conversation with a high-revenue practitioner when care evidence requires intervention.

Technology will support, not disguise, the reset. The CEO will select a small number of leading indicators that local teams can act upon, test the reliability of source data and remove duplicate reporting that consumes clinical time. Alerts require ownership and response standards. Automation introduced into triage or scheduling must be monitored for missed urgency and unequal access.

External confidence will be rebuilt through precise disclosure. Regulators, payers, partners and community referrers should hear what happened, what remains uncertain and how improvement is being verified. The CEO will not announce victory on the strength of a short incident-free interval. Independent review and sustained process evidence will determine when enhanced oversight can step down.

What you will own

• The network clinical-recovery plan and board assurance narrative.
• Site leadership, operating standards and escalation authority.
• Workforce establishment, clinical supervision and leadership conduct.
• Patient-flow, referral, discharge and continuity performance.
• Capital allocation, service-line choices and benefits delivery.
• Medical-practitioner governance with accountable clinical officers.
• Relationships with regulators, payers, referrers and partners.
• A succession bench able to sustain improvement after recovery.

The first 12 months

During the first 30 days, meet frontline teams on every major pathway, examine a representative case set and identify where reporting differs from lived practice. Agree immediate safeguards for any uncontrolled risk and give the board a candid baseline.

By month four, install joint site accountability, standardise high-risk transition controls and establish weekly recovery reviews driven by patient cases and operational evidence. Confirm the workforce and capital interventions needed for fragile services.

At twelve months, reduce overdue high-risk follow-up by at least 70%, cut avoidable unplanned transfers by 25% and achieve 95% verified closure of serious-review actions within agreed dates. Agency hours in core services should fall by 20% without worsening vacancies, and no site should operate an unapproved critical-control workaround.

What the board will examine

• Whether adverse information travels quickly and intact.
• Whether site leaders can explain risk without central coaching.
• Whether patients experience dependable transitions and response.
• Whether workforce decisions reflect acuity rather than averages.
• Whether capital has moved towards the largest clinical exposures.
• Whether improvement survives normal demand and leadership absence.

The person

You offer at least 28 years in complex healthcare delivery, including full executive accountability across multiple sites and direct leadership through a documented quality recovery. Your evidence should cover regulated clinical operations, material capital allocation, medical-practitioner relationships and a workforce exceeding 500 employees or equivalent partner scale.

The board expects intellectual honesty under pressure. You can separate a regrettable outcome from a controllable process failure, protect due process and still act decisively. Experience in the United States is essential; international governance exposure and prior board accountability will strengthen your candidacy. Boston is the operating anchor under a hybrid model, with frequent site presence.

Compensation and terms

Base compensation is USD 500,000–750,000 plus annual incentive and long-term participation linked to quality recovery, access, workforce stability, capital discipline and leadership depth. This is a permanent hybrid appointment based in Boston, reporting to the Group board and Group Chief Executive. The urgent timetable reflects active clinical-recovery work.

Confidentiality

The organisation, facilities, practitioners, patients, incidents, payers and partners are confidential. Further evidence is released only after suitability, conflicts and a signed confidentiality undertaking are established. Candidates must not contact healthcare organisations or clinicians to infer the client.